(NASDAQ: IBIO) Ibio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Ibio's earnings in 2026 is -$27,606,000.On average, 8 Wall Street analysts forecast IBIO's earnings for 2026 to be -$16,125,661, with the lowest IBIO earnings forecast at -$17,039,746, and the highest IBIO earnings forecast at -$14,605,497. On average, 7 Wall Street analysts forecast IBIO's earnings for 2027 to be -$14,675,047, with the lowest IBIO earnings forecast at -$18,987,146, and the highest IBIO earnings forecast at -$9,806,548.
In 2027, IBIO is forecast to generate -$14,675,047 in earnings, with the lowest earnings forecast at -$18,987,146 and the highest earnings forecast at -$9,806,548.